IL293388B2 - History of Benzylamide as Inhibitors of Transforming Growth Factor Receptor I/ALK5 - Google Patents

History of Benzylamide as Inhibitors of Transforming Growth Factor Receptor I/ALK5

Info

Publication number
IL293388B2
IL293388B2 IL293388A IL29338822A IL293388B2 IL 293388 B2 IL293388 B2 IL 293388B2 IL 293388 A IL293388 A IL 293388A IL 29338822 A IL29338822 A IL 29338822A IL 293388 B2 IL293388 B2 IL 293388B2
Authority
IL
Israel
Prior art keywords
alk5
inhibitors
growth factor
transforming growth
beta receptor
Prior art date
Application number
IL293388A
Other languages
English (en)
Hebrew (he)
Other versions
IL293388B1 (en
IL293388A (en
Original Assignee
Agomab Spain S L U
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agomab Spain S L U filed Critical Agomab Spain S L U
Publication of IL293388A publication Critical patent/IL293388A/en
Publication of IL293388B1 publication Critical patent/IL293388B1/en
Publication of IL293388B2 publication Critical patent/IL293388B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IL293388A 2019-11-28 2020-11-27 History of Benzylamide as Inhibitors of Transforming Growth Factor Receptor I/ALK5 IL293388B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19383057 2019-11-28
PCT/EP2020/083566 WO2021105317A1 (en) 2019-11-28 2020-11-27 Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Publications (3)

Publication Number Publication Date
IL293388A IL293388A (en) 2022-07-01
IL293388B1 IL293388B1 (en) 2025-12-01
IL293388B2 true IL293388B2 (en) 2026-04-01

Family

ID=68808255

Family Applications (1)

Application Number Title Priority Date Filing Date
IL293388A IL293388B2 (en) 2019-11-28 2020-11-27 History of Benzylamide as Inhibitors of Transforming Growth Factor Receptor I/ALK5

Country Status (16)

Country Link
US (2) US12297186B2 (enExample)
EP (1) EP4065572A1 (enExample)
JP (2) JP7808032B2 (enExample)
KR (1) KR20220107180A (enExample)
CN (1) CN114787145B (enExample)
AR (1) AR120578A1 (enExample)
AU (1) AU2020394531A1 (enExample)
BR (1) BR112022010251A2 (enExample)
CA (1) CA3160963A1 (enExample)
ES (1) ES3029608T1 (enExample)
IL (1) IL293388B2 (enExample)
MX (1) MX2022005843A (enExample)
PH (1) PH12022551177A1 (enExample)
SA (1) SA522432749B1 (enExample)
WO (1) WO2021105317A1 (enExample)
ZA (1) ZA202205149B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3978487A1 (en) 2020-09-30 2022-04-06 Origo Biopharma, S.L. 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
WO2025176835A1 (en) 2024-02-22 2025-08-28 Agomab Spain S.L.U. Crystalline phase forms of a benzylamide derivative
WO2026082960A1 (en) 2024-10-18 2026-04-23 Agomab Therapeutics Nv 1,5-naphtyridine and quinoline based inhibitors of alk5
WO2026082968A1 (en) 2024-10-18 2026-04-23 Agomab Therapeutics Nv Novel compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3621540A1 (de) 1986-06-27 1988-01-07 Basf Ag Chinolinderivate, verfahren zu ihrer herstellung, diese enthaltende mikrobizide und ihre verwendung zur bekaempfung von bakterien und pilzen
US20040087623A1 (en) 2001-02-02 2004-05-06 Gellibert Francoise Jeanne Pyrazole derivatives against tgf overexpression
OA12929A (en) 2002-09-18 2006-10-13 Pfizer Prod Inc Pyrazole derivatives as transforming growth (TGF) inhibitors.
AU2003268155A1 (en) 2002-09-19 2004-04-08 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
WO2009123316A1 (ja) 2008-04-04 2009-10-08 武田薬品工業株式会社 複素環誘導体及びその用途
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
BR112012018358A2 (pt) 2009-12-21 2016-08-09 Bayer Cropscience Ag tienilpiri(mi)dinilazol e seu uso para controlar fungos fitopatogênicos
AU2012281281B2 (en) * 2011-07-13 2017-06-01 Tiumbio Co., Ltd 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
US11021468B2 (en) * 2015-04-01 2021-06-01 Rigel Pharmaceuticals, Inc. TGF-ß inhibitors
US11040976B2 (en) 2015-04-24 2021-06-22 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof
KR102434226B1 (ko) * 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
CA3091533A1 (en) 2018-03-02 2019-09-06 Universite De Lausanne Pyrazole derivatives as inhibitors of the wnt signalling pathway
US11945803B2 (en) 2018-08-07 2024-04-02 Tosk, Inc. Modulators of RAS GTPase
CN110433164A (zh) 2019-08-15 2019-11-12 南开大学 TGF-beta受体分子抑制剂在治疗小鼠动物模型中急性髓系白血病的应用
EP3978487A1 (en) 2020-09-30 2022-04-06 Origo Biopharma, S.L. 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Also Published As

Publication number Publication date
US12297186B2 (en) 2025-05-13
SA522432749B1 (ar) 2025-05-12
WO2021105317A1 (en) 2021-06-03
CA3160963A1 (en) 2021-06-03
KR20220107180A (ko) 2022-08-02
AU2020394531A1 (en) 2022-06-09
IL293388B1 (en) 2025-12-01
MX2022005843A (es) 2022-07-19
ZA202205149B (en) 2025-06-25
CN114787145A (zh) 2022-07-22
US20230025933A1 (en) 2023-01-26
PH12022551177A1 (en) 2024-02-05
BR112022010251A2 (pt) 2022-09-06
JP2023504795A (ja) 2023-02-07
EP4065572A1 (en) 2022-10-05
JP7808032B2 (ja) 2026-01-28
US20250333395A1 (en) 2025-10-30
IL293388A (en) 2022-07-01
AR120578A1 (es) 2022-02-23
ES3029608T1 (en) 2025-06-24
JP2025163046A (ja) 2025-10-28
CN114787145B (zh) 2024-03-26

Similar Documents

Publication Publication Date Title
PT4061812T (pt) Compostos úteis como inibidores da proteína helios
IL282552A (en) Crystalline forms of MNK inhibitors
IL277518A (en) Inhibitors of PRMT5
IL289878A (en) Tricyclic amides as inhibitors of cd38
EP3982949A4 (en) MRSA1 INHIBITORS
HUE071024T2 (hu) Szubsztituált aminotiazolok mint immun aktiválásra alkalmas dgkzeta inhibitorok
IL268625A (en) Amino pyrimidine compounds used as SSAO inhibitors
IL301663B2 (en) History of 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide as inhibitors of transforming growth factor receptor I/ALK5 in cells
MX2016005297A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos.
EP3969442A4 (en) FIBROBLAST GROWTH FACTOR RECEPTOR KINASE INHIBITORS
EP4028013A4 (en) MRSA1 INHIBITORS
ZA202002041B (en) Epidermal growth factor receptor inhibitors
IL276887A (en) History of novel chromium as TCR-NCK interaction inhibitors
EP3687514A4 (en) METHODS AND COMPOSITIONS FOR INHIBITING STAT3
IL309447A (en) Pharmaceutical preparations of epidermal growth factor receptor inhibitor
HUE067997T2 (hu) Szubsztituált 2-tiazolinok mint nitrifikációs inhibitorok
HK40082084A (en) Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
SG10201909596RA (en) Synthesis of Tyrosine Kinase Inhibitors
SG11202002267UA (en) Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase
ZA202100140B (en) Pyridopyrimidinone derivatives for use as axl inhibitors
ZA201908372B (en) Pyridoquinazoline derivatives useful as protein kinase inhibitors
HK40097824A (en) 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
HK40075513A (en) Heterobicyclic amides as inhibitors of cd38
IL317760A (en) History of benzocarbazoles as DRP1 inhibitors
HK40082014A (en) Inhibitors of hif-2alpha